The latest C-suite moves in pharma; a 'flawed' giveaway for antibiotic drug development

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     STAT+: A 'blank check': Bill to boost antibiotic development blasted as a 'flawed' giveaway to pharma By Ed Silverman Melissa Brower/Centers for Disease Control and Prevention via AP A coalition is urging Congress not to pass legislation to reward drug companies for developing new antibiotics. Read More STAT+: U.S. Supreme Court gives Amgen a boost by agreeing to review a closely watched patent case By Ed Silverman Adobe At issue is a long-running battle between Amgen and a pair of rivals over the market for injectable cholesterol treatments. Read More Pfizer, BioNTech report new Covid booster is more protective against recent Omicron variants than original vaccine By Helen Branswell Cindy Ord/Getty Images for Pfizer/BioNTech Neutralizing antibodies targeting Omicron BA.4/BA.5 viruses were four-fold higher in people aged 55 and older who received the bivalent booster. Read More Sponsored Insight by Kx Advisors Pre-commercial pharma and biotech companies face ever-increasing costs, complexities in drug launch As costs of developing new drugs grow, now more than ever, specialty pharmaceuticals must achieve immediate success following launch. However, developing a launch strategy for direct commercialization includes unique challenges for pre-revenue companies. With more than a third of all therapies failing to meet market expectations in the launch year, how do you define success for your commercial organization? What are the keys to an effective launch to establish a profitable trajectory? Find out here. STAT+: Up and down the ladder: The latest comings and goings By Ed Silverman Alex Hogan/STAT From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. Read More Opinion: Believers in science must take action when recommendations breach public health By Scott Rivkees Adobe When officials make recommendations that endanger public health, those who believe in the foundation of science must take action. Read More STAT+: Following your gut: How scientists are getting closer to linking the microbiome and chronic diseases By Isabella Cueto Adobe Several recent findings show how researchers are using new tools to push forward a field that has had a tumultuous few years. Read More Friday, November 4, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser